MCID: ATY042
MIFTS: 51

Atypical Chronic Myeloid Leukemia

Categories: Cancer diseases, Blood diseases, Rare diseases, Immune diseases

Aliases & Classifications for Atypical Chronic Myeloid Leukemia

MalaCards integrated aliases for Atypical Chronic Myeloid Leukemia:

Name: Atypical Chronic Myeloid Leukemia 12 12 55 14
Subacute Myeloid Leukemia 12 55 14
Leukemia, Myeloid, Chronic, Atypical, Bcr-Abl Negative 41 69
Atypical Chronic Myeloid Leukemia Bcr-Abl1 Negative 12
Subacute Granulocytic Leukemia 12
Subacute Myelogenous Leukemia 12
Atypical Cml 12
Acml 12

Characteristics:

Orphanet epidemiological data:

55
atypical chronic myeloid leukemia
Age of onset: Adult;

Classifications:



External Ids:

Disease Ontology 12 DOID:0060597 DOID:8747
ICD10 32 C92.2
MeSH 41 D054438
NCIt 46 C3519
SNOMED-CT 64 95278004
Orphanet 55 ORPHA98824
MESH via Orphanet 42 D054438
UMLS via Orphanet 70 C0349640 C1292772
ICD10 via Orphanet 33 C92.2

Summaries for Atypical Chronic Myeloid Leukemia

Disease Ontology : 12 A myelodysplastic myeloproliferative neoplasm characterized by the principal involvement of the neutrophil series with leukocytosis and multilineage dysplasia. The neoplastic cells do not have a Philadelphia chromosome or the BCR/ABL fusion gene.

MalaCards based summary : Atypical Chronic Myeloid Leukemia, also known as subacute myeloid leukemia, is related to leukemia, chronic myeloid and chronic neutrophilic leukemia. An important gene associated with Atypical Chronic Myeloid Leukemia is CSF3R (Colony Stimulating Factor 3 Receptor), and among its related pathways/superpathways are Endometrial cancer and PI3K-Akt signaling pathway. The drugs Cytarabine and Busulfan have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 72 Atypical chronic myeloid leukemia (aCML) is a type of leukemia. It is a heterogeneous disorder belonging... more...

Related Diseases for Atypical Chronic Myeloid Leukemia

Diseases related to Atypical Chronic Myeloid Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 34)
# Related Disease Score Top Affiliating Genes
1 leukemia, chronic myeloid 31.3 ABL1 JAK2 PDGFRA RUNX1 SETBP1
2 chronic neutrophilic leukemia 29.4 ASXL1 CSF3R SETBP1
3 chronic myelomonocytic leukemia 29.0 ASXL1 JAK2 RUNX1 SETBP1
4 myelodysplastic myeloproliferative cancer 28.6 ASXL1 CSF3R JAK2 SETBP1
5 myeloproliferative neoplasm 28.4 ABL1 CSF3R FGFR1 JAK2 PDGFRA
6 leukemia 10.6
7 myeloid leukemia 10.6
8 pdgfrb-associated chronic eosinophilic leukemia 10.2
9 primary hypereosinophilic syndrome 10.1 FGFR1 PDGFRA
10 splenomegaly 10.1 JAK2 SETBP1
11 leukocyte disease 9.9 CSF3R PDGFRA
12 refractory anemia with excess blasts 9.9 ASXL1 SETBP1
13 thrombocytopenia-absent radius syndrome 9.9 FGFR1 JAK2
14 sm-ahnmd 9.9 ASXL1 PDGFRA
15 core binding factor acute myeloid leukemia 9.9 JAK2 RUNX1
16 chronic eosinophilic leukemia 9.9 ABL1 FGFR1 PDGFRA
17 large cell carcinoma 9.8 FGFR1 PDGFRA
18 8p11 myeloproliferative syndrome 9.8 FGFR1 RUNX1
19 myeloid and lymphoid neoplasms with eosinophilia and abnormalities of pdgfra, pdgfrb, and fgfr1 9.8 FGFR1 JAK2 PDGFRA
20 hypereosinophilic syndrome 9.8 ABL1 FGFR1 PDGFRA
21 systemic mastocytosis 9.8 FGFR1 JAK2 PDGFRA
22 acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22) 9.8
23 tetrasomy 21 9.8
24 leukemia, acute lymphoblastic 3 9.8 ABL1 PDGFRA RUNX1
25 budd-chiari syndrome 9.7 JAK2 PDGFRA
26 hematologic cancer 9.7 ABL1 JAK2 RUNX1
27 lymphoblastic leukemia 9.6 ABL1 JAK2 RUNX1
28 juvenile myelomonocytic leukemia 9.5 JAK2 PDGFRA RUNX1 SETBP1
29 essential thrombocythemia 9.5 ABL1 ASXL1 JAK2
30 refractory anemia 9.4 ASXL1 JAK2 RUNX1
31 polycythemia vera 9.3 ABL1 ASXL1 JAK2 PDGFRA
32 bone marrow cancer 8.7 ABL1 CSF3R FGFR1 JAK2 PDGFRA RUNX1
33 leukemia, acute myeloid 8.5 ABL1 ASXL1 CSF3R JAK2 RUNX1 SETBP1
34 myelodysplastic syndrome 8.5 ABL1 ASXL1 CSF3R JAK2 RUNX1 SETBP1

Graphical network of the top 20 diseases related to Atypical Chronic Myeloid Leukemia:



Diseases related to Atypical Chronic Myeloid Leukemia

Symptoms & Phenotypes for Atypical Chronic Myeloid Leukemia

GenomeRNAi Phenotypes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

25 (show all 22)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-107 9.72 CSF3R
2 Increased shRNA abundance (Z-score > 2) GR00366-A-122 9.72 SETBP1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-123 9.72 CSF3R
4 Increased shRNA abundance (Z-score > 2) GR00366-A-129 9.72 PDGFRA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-136 9.72 CSF3R
6 Increased shRNA abundance (Z-score > 2) GR00366-A-146 9.72 PDGFRA SETBP1 CSF3R
7 Increased shRNA abundance (Z-score > 2) GR00366-A-157 9.72 SETBP1
8 Increased shRNA abundance (Z-score > 2) GR00366-A-164 9.72 SETBP1 CSF3R
9 Increased shRNA abundance (Z-score > 2) GR00366-A-168 9.72 CSF3R
10 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.72 SETBP1
11 Increased shRNA abundance (Z-score > 2) GR00366-A-185 9.72 SETBP1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-190 9.72 SETBP1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-194 9.72 SETBP1
14 Increased shRNA abundance (Z-score > 2) GR00366-A-197 9.72 CSF3R
15 Increased shRNA abundance (Z-score > 2) GR00366-A-207 9.72 PDGFRA
16 Increased shRNA abundance (Z-score > 2) GR00366-A-32 9.72 PDGFRA
17 Increased shRNA abundance (Z-score > 2) GR00366-A-49 9.72 PDGFRA
18 Increased shRNA abundance (Z-score > 2) GR00366-A-7 9.72 CSF3R
19 Increased shRNA abundance (Z-score > 2) GR00366-A-73 9.72 PDGFRA
20 Increased shRNA abundance (Z-score > 2) GR00366-A-8 9.72 SETBP1
21 Increased shRNA abundance (Z-score > 2) GR00366-A-81 9.72 SETBP1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.72 SETBP1

MGI Mouse Phenotypes related to Atypical Chronic Myeloid Leukemia:

43
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 9.91 ASXL1 RUNX1 CSF3R FGFR1 JAK2 ABL1
2 endocrine/exocrine gland MP:0005379 9.87 CSF3R FGFR1 JAK2 ABL1 PDGFRA ASXL1
3 hematopoietic system MP:0005397 9.8 ASXL1 RUNX1 CSF3R FGFR1 JAK2 ABL1
4 immune system MP:0005387 9.7 ASXL1 RUNX1 CSF3R FGFR1 JAK2 ABL1
5 mortality/aging MP:0010768 9.56 ASXL1 RUNX1 SETBP1 CSF3R FGFR1 JAK2
6 skeleton MP:0005390 9.1 ASXL1 RUNX1 FGFR1 JAK2 ABL1 PDGFRA

Drugs & Therapeutics for Atypical Chronic Myeloid Leukemia

Drugs for Atypical Chronic Myeloid Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 307)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
2
Busulfan Approved, Investigational Phase 3,Phase 2,Phase 1 55-98-1 2478
3
Cyclophosphamide Approved, Investigational Phase 3,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
5
Hydroxyurea Approved Phase 3,Phase 2 127-07-1 3657
6
Idarubicin Approved Phase 3 58957-92-9 42890
7
Lenograstim Approved, Investigational Phase 3,Phase 1,Phase 2 135968-09-1
8
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
9
Azacitidine Approved, Investigational Phase 3,Phase 1 320-67-2 9444
10
Decitabine Approved, Investigational Phase 3,Phase 1 2353-33-5 451668
11
Miconazole Approved, Investigational, Vet_approved Phase 3,Phase 2,Phase 1 22916-47-8 4189
12
Fludarabine Approved Phase 3,Phase 2,Phase 1 21679-14-1, 75607-67-9 30751
13
Mycophenolate mofetil Approved, Investigational Phase 3,Phase 2,Phase 1 128794-94-5 5281078
14
Mycophenolic acid Approved Phase 3,Phase 2,Phase 1 24280-93-1 446541
15
Ephedrine Approved Phase 3 299-42-3 9294
16
Pseudoephedrine Approved Phase 3 90-82-4 7028
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Daunorubicin Approved Phase 3 20830-81-3 30323
19
Mitoxantrone Approved, Investigational Phase 3,Phase 2 65271-80-9 4212
20
Thioguanine Approved Phase 3 154-42-7 2723601
21
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 38904 498142
22
Melphalan Approved Phase 2, Phase 3,Phase 1 148-82-3 460612 4053
23 Thiotepa Approved, Investigational Phase 2, Phase 3,Phase 1 52-24-4 5453
24
Estradiol Approved, Investigational, Vet_approved Phase 3 50-28-2 5757
25
Ethinyl Estradiol Approved Phase 3 57-63-6 5991
26
Moxifloxacin Approved, Investigational Phase 3 151096-09-2, 354812-41-2 152946
27
Norgestimate Approved, Investigational Phase 3 35189-28-7 6540478
28
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
29
Tretinoin Approved, Investigational, Nutraceutical Phase 3,Phase 1 302-79-4 5538
30 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
31 6-Mercaptopurine Phase 3
32 Anti-Infective Agents Phase 3,Phase 2,Phase 1
33 Antimetabolites Phase 3,Phase 2,Phase 1
34 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
35 Antiviral Agents Phase 3,Phase 2,Phase 1
36 Immunosuppressive Agents Phase 3,Phase 2,Phase 1
37 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2,Phase 1,Early Phase 1
38 Alkylating Agents Phase 3,Phase 2,Phase 1
39 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
40 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
41 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
42 Antirheumatic Agents Phase 3,Phase 2,Phase 1
43 Etoposide phosphate Phase 3,Phase 2,Phase 1
44 Interferon-alpha Phase 3,Phase 2
45 interferons Phase 3,Phase 2
46 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
47 Analgesics Phase 3,Phase 2,Phase 1
48 Anesthetics Phase 3
49 Anesthetics, Dissociative Phase 3
50 Anesthetics, General Phase 3

Interventional clinical trials:

(show top 50) (show all 204)

# Name Status NCT ID Phase Drugs
1 Donor Stem Cell Transplant With or Without Chemotherapy in Treating Children With Primary Myelodysplastic Syndrome Unknown status NCT00047268 Phase 3 cytarabine;mercaptopurine
2 Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia Unknown status NCT00025402 Phase 3 busulfan;cyclophosphamide;cytarabine;etoposide;hydroxyurea;idarubicin
3 Ketamine Hydrochloride and Best Pain Management in Treating Cancer Patients With Neuropathic Pain Unknown status NCT01316744 Phase 3 ketamine hydrochloride
4 Low-Dose Decitabine Compared With Standard Supportive Care in Treating Older Patients With Myelodysplastic Syndrome Unknown status NCT00043134 Phase 3 decitabine
5 Internet-Based Program With or Without Telephone-Based Problem-Solving Training in Helping Long-Term Survivors of Hematopoietic Stem Cell Transplant Cope With Late Complications Completed NCT00799461 Phase 3
6 Laboratory-Treated Donor Bone Marrow in Treating Patients Who Are Undergoing a Donor Bone Marrow Transplant for Hematologic Cancer Completed NCT00265837 Phase 3
7 Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00045292 Phase 3 acyclovir;acyclovir sodium;valacyclovir
8 A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families Completed NCT00782145 Phase 3
9 Cyclosporine Eye Drops in Preventing Graft-Versus-Host Disease of the Eye in Patients Who Have Undergone Donor Stem Cell Transplant for Hematologic Cancer or Bone Marrow Failure Disorder Completed NCT00755040 Phase 3 cyclosporine ophthalmic emulsion
10 Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain Completed NCT00666211 Phase 3
11 Personalized Information or Basic Information in Helping Patients Make Decisions About Participating in a Clinical Trial Completed NCT00750009 Phase 3
12 American Ginseng in Treating Patients With Fatigue Caused by Cancer Completed NCT00719563 Phase 3 American ginseng
13 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Music Therapy or Book Discussion in Improving Quality of Life in Young Patients Undergoing Stem Cell Transplant Completed NCT00305851 Phase 3
15 Combination Chemotherapy With or Without Filgrastim and/or Tretinoin in Treating Patients With Acute Myeloid Leukemia Completed NCT00005863 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;fludarabine phosphate;tretinoin
16 Intensive Compared With Nonintensive Chemotherapy in Treating Older Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Completed NCT00005823 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;hydroxyurea;idarubicin;mitoxantrone hydrochloride;thioguanine;tretinoin;valspodar
17 Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
18 Mycophenolate Mofetil (MMF) for Treatment of Chronic Graft-versus-host Disease (GVHD) Terminated NCT00089141 Phase 3 mycophenolate mofetil;placebo
19 Moxifloxacin in Preventing Bacterial Infections in Patients Who Have Undergone Donor Stem Cell Transplant Terminated NCT00324324 Phase 3 moxifloxacin hydrochloride;Placebo
20 Total-Body Irradiation, Fludarabine, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Unknown status NCT00044954 Phase 2 cyclosporine;fludarabine phosphate;mycophenolate mofetil
21 Light-Emitting Diode Therapy in Preventing Mucositis in Children Receiving Chemotherapy With or Without Radiation Therapy Before Bone Marrow Transplantation Unknown status NCT00036712 Phase 2
22 Arsenic Trioxide in Treating Patients With Myelodysplastic Syndromes Unknown status NCT00020969 Phase 2 arsenic trioxide
23 Umbilical Cord Blood and Placental Blood Transplantation in Treating Patients With Hematologic Cancer or Aplastic Anemia Unknown status NCT00008164 Phase 2
24 Tipifarnib in Treating Patients With Myeloproliferative Disorders Unknown status NCT00005846 Phase 1, Phase 2 tipifarnib
25 Imatinib (Gleevec(Registered Trademark)) to Treat Chronic Myelomonocytic Leukemia and Atypical Chronic Myelogenous Leukemia Completed NCT00079313 Phase 2 Imatinib
26 Combination Chemotherapy and Interferon Alfa in Treating Patients With Chronic Myelogenous Leukemia Completed NCT00002598 Phase 2 cyclophosphamide;cytarabine;etoposide;methotrexate;mitoxantrone hydrochloride
27 Anti-Thymocyte Globulin and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00217386 Phase 2
28 Combination Chemotherapy Plus Bone Marrow or Peripheral Stem Cell Transplantation in Treating Patients With Myeloproliferative Disorders Completed NCT00002792 Phase 2 busulfan;cyclophosphamide;cyclosporine;methotrexate;tacrolimus
29 Monoclonal Antibody Plus Interleukin-2 in Treating Patients With Leukemia or Lymphoma Completed NCT00002681 Phase 1, Phase 2
30 Beclomethasone Dipropionate in Preventing Acute Graft-Versus-Host Disease in Patients Undergoing a Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00489203 Phase 2 beclomethasone dipropionate;placebo;tacrolimus;methotrexate
31 Tipifarnib in Treating Patients With Chronic Myeloid Leukemia, Chronic Myelomonocytic Leukemia, or Undifferentiated Myeloproliferative Disorders Completed NCT02210858 Phase 1, Phase 2 Tipifarnib
32 3-AP and Fludarabine in Treating Patients With Myeloproliferative Disorders, Chronic Myelomonocytic Leukemia, or Accelerated Phase or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00381550 Phase 2 fludarabine phosphate;triapine
33 Ondansetron in Preventing Nausea and Vomiting in Patients Undergoing Stem Cell Transplant Completed NCT00795769 Phase 2 ondansetron
34 Alemtuzumab, Fludarabine Phosphate, and Total-Body Irradiation Followed by Cyclosporine and Mycophenolate Mofetil in Treating Patients Who Are Undergoing Donor Stem Cell Transplant for Hematologic Cancer Completed NCT00118352 Phase 2 fludarabine phosphate;cyclosporine;mycophenolate mofetil
35 Arsenic Trioxide and Etanercept in Treating Patients With Myelodysplastic Syndromes Completed NCT00093366 Phase 1, Phase 2 arsenic trioxide
36 Doxercalciferol in Treating Patients With Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia Completed NCT00052832 Phase 2
37 Cholecalciferol in Treating Patients With Myelodysplastic Syndrome Completed NCT00068276 Phase 2
38 Arsenic Trioxide, Ascorbic Acid, Dexamethasone, and Thalidomide in Myelofibrosis/Myeloproliferative Disorder Completed NCT00274820 Phase 2 arsenic trioxide;dexamethasone;thalidomide
39 Sirolimus, Tacrolimus, and Methotrexate in Preventing Acute Graft-Versus-Host Disease in Patients With Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00089037 Phase 1, Phase 2 methotrexate;sirolimus;tacrolimus
40 Busulfan, Cyclophosphamide, and Antithymocyte Globulin Followed by Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer Completed NCT00611351 Phase 2 busulfan;cyclophosphamide;mycophenolate mofetil;tacrolimus
41 Alemtuzumab and Glucocorticoids in Treating Newly Diagnosed Acute Graft-Versus-Host Disease in Patients Who Have Undergone a Donor Stem Cell Transplant Completed NCT00410657 Phase 2 methylprednisolone;prednisone
42 Methotrexate and Glucocorticoids in Treating Patients With Newly Diagnosed Acute Graft-Versus-Host Disease After Donor Stem Cell Transplant Completed NCT00357084 Phase 2 methotrexate;methylprednisolone;prednisone
43 Fludarabine and Busulfan Followed by Donor Peripheral Stem Cell Transplant and Antithymocyte Globulin, Tacrolimus, and Methotrexate in Treating Patients With Myeloid Cancer Completed NCT00346359 Phase 2 busulfan;fludarabine phosphate;methotrexate;tacrolimus
44 Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer Completed NCT00237627 Phase 1, Phase 2 PS-341;Doxil;Velcade
45 Campath-1H + FK506 and Methylprednisolone for GVHD Completed NCT00109993 Phase 2 methylprednisolone;tacrolimus
46 Tacrolimus and Mycophenolate Mofetil in Preventing Acute Graft-Versus-Host Disease in Patients With Advanced Hematologic Cancer Who Are Undergoing Donor Stem Cell Transplantation Completed NCT00096096 Phase 2 mycophenolate mofetil;tacrolimus
47 Pilot Study Of Unrelated UCB Transplant for Non-Malignant Hematologic Conditions Completed NCT00003336 Phase 2 busulfan;cyclophosphamide;melphalan;methylprednisolone
48 Cyproheptadine and Megestrol in Preventing Weight Loss in Children With Cachexia Caused By Cancer or Cancer Treatment Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
49 High-Dose Chemotherapy, Total-Body Irradiation, and Autologous Stem Cell Transplantation or Bone Marrow Transplantation in Treating Patients With Hematologic Cancer or Solid Tumors Completed NCT00060255 Phase 2 busulfan;carboplatin;carmustine;cyclophosphamide;etoposide;melphalan;thiotepa
50 Peripheral Stem Cell Transplantation in Treating Patients With Breast Cancer or Hematologic Cancer Completed NCT00006225 Phase 1, Phase 2

Search NIH Clinical Center for Atypical Chronic Myeloid Leukemia

Cochrane evidence based reviews: leukemia, myeloid, chronic, atypical, bcr-abl negative

Genetic Tests for Atypical Chronic Myeloid Leukemia

Anatomical Context for Atypical Chronic Myeloid Leukemia

MalaCards organs/tissues related to Atypical Chronic Myeloid Leukemia:

38
Myeloid, Bone, Bone Marrow, Neutrophil, Breast, Liver, T Cells

Publications for Atypical Chronic Myeloid Leukemia

Articles related to Atypical Chronic Myeloid Leukemia:

(show all 42)
# Title Authors Year
1
Atypical chronic myeloid leukemia: a rare entity with management challenges. ( 29226717 )
2018
2
Recent Progress in Chronic Neutrophilic Leukemia and Atypical Chronic Myeloid Leukemia. ( 28983816 )
2017
3
Identification of a novel CSF3R-SPTAN1 fusion gene in an atypical chronic myeloid leukemia patient with t(1;9)(p34;q34) by RNA-Seq. ( 29025591 )
2017
4
Targeted next generation sequencing and identification of risk factors in World Health Organization defined atypical chronic myeloid leukemia. ( 28314085 )
2017
5
Atypical chronic myeloid leukemia in a German Shepherd Dog. ( 28205462 )
2017
6
Atypical chronic myeloid leukemia with isochromosome (X)(p10): A case report. ( 28927137 )
2017
7
Sudden Intracranial Hemorrhage in a Patient With Atypical Chronic Myeloid Leukemia in Chronic Phase. ( 29227326 )
2017
8
Atypical Chronic Myeloid Leukemia in Two Pediatric Patients. ( 26274939 )
2016
9
How I treat atypical chronic myeloid leukemia. ( 27899359 )
2016
10
Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, in a 5-Month Baby - ARare Presentation. ( 28666496 )
2016
11
Leukemia cutis presenting as scaly plaques in a Christmas tree distribution in a patient with atypical chronic myeloid leukemia. ( 27853001 )
2016
12
Activity of single-agent decitabine in atypical chronic myeloid leukemia. ( 26378157 )
2016
13
Decitabine for the treatment of atypical chronic myeloid leukemia: A report of two cases. ( 26870268 )
2016
14
Recurrent ETNK1 mutations in atypical chronic myeloid leukemia. ( 25343957 )
2015
15
Centromeric fragment of chromosome 7 in atypical chronic myeloid leukemia with the SET binding protein 1 gene mutation. ( 24991718 )
2015
16
A novel mutation of SETBP1 in atypical chronic myeloid leukemia transformed from acute myelomonocytic leukemia. ( 26185647 )
2015
17
Transformation from atypical chronic myeloid leukemia to chronic myelomonocytic leukemia as progression of myeloid neoplasm with platelet-derived growth factor A9 rearrangement. ( 26881541 )
2015
18
Efficacy and side-effects of decitabine in treatment of atypical chronic myeloid leukemia. ( 25426665 )
2015
19
Durable Disease Control with MEK Inhibition in a Patient with NRAS-mutated Atypical Chronic Myeloid Leukemia. ( 26870618 )
2015
20
Evaluation of a father and son with atypical chronic myeloid leukemia with SETBP1 mutations and a review of the literature. ( 26017341 )
2015
21
Atypical chronic myeloid leukemia with concomitant CSF3R T618I and SETBP1 mutations unresponsive to the JAK inhibitor ruxolitinib. ( 25491280 )
2015
22
Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia. ( 25239264 )
2014
23
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms. ( 24627528 )
2014
24
Molecular genetics of chronic neutrophilic leukemia, chronic myelomonocytic leukemia and atypical chronic myeloid leukemia. ( 25498990 )
2014
25
Significant clinical response to JAK1/2 inhibition in a patient with CSF3R-T618I-positive atypical chronic myeloid leukemia. ( 25180155 )
2014
26
Establishment and characterization of a rare atypical chronic myeloid leukemia cell line NT-1. ( 25012564 )
2014
27
Successful transplantation of ethnically mismatched cord blood in a boy with atypical chronic myeloid leukemia. ( 23264127 )
2013
28
A BCR-JAK2 fusion gene from ins(22;9)(q11;p13p24) in a patient with atypical chronic myeloid leukemia. ( 23432689 )
2013
29
Atypical chronic myeloid leukemia with t(9;22)(p24,11.2), a BCR-JAK2 fusion gene. ( 23904814 )
2013
30
Atypical chronic myeloid leukemia harboring NUP98-HOXA9. ( 23754767 )
2013
31
Recurrent SETBP1 mutations in atypical chronic myeloid leukemia. ( 23222956 )
2013
32
Chronic myelomonocytic leukemia and atypical chronic myeloid leukemia: novel pathogenetic lesions. ( 22289493 )
2012
33
JAK2 mutation and atypical chronic myeloid leukemia. ( 19427035 )
2009
34
The role of peripheral blood, bone marrow aspirate and especially bone marrow trephine biopsy in distinguishing atypical chronic myeloid leukemia from chronic granulocytic leukemia and chronic myelomonocytic leukemia. ( 19500135 )
2009
35
t(3;21)(q22;q22) leading to truncation of the RYK gene in atypical chronic myeloid leukemia. ( 19168282 )
2009
36
Atypical chronic myeloid leukemia as defined in the WHO classification is a JAK2 V617F negative neoplasm. ( 18555525 )
2008
37
Two clonal occurrences of tetrasomy 21 in an atypical chronic myeloid leukemia with wild-type RUNX1 alleles. Additional support for a gene dosage effect of chromosome 21 or RUNX1 in leukemia. ( 15339695 )
2004
38
Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia. ( 15034867 )
2004
39
Imatinib mesylate elicits positive clinical response in atypical chronic myeloid leukemia involving the platelet-derived growth factor receptor beta. ( 14504072 )
2003
40
Translocation t(9;22) (p23;q11) in atypical chronic myeloid leukemia (aCML) presenting osteolytic lesions. ( 12463598 )
2002
41
A diagnostic dilemma: chronic myelomonocytic leukemia versus atypical chronic myeloid leukemia. A case report and review of the literature. ( 9401502 )
1997
42
[Atypical chronic myeloid leukemia with polymorphism of the BCR gene]. ( 1687492 )
1991

Variations for Atypical Chronic Myeloid Leukemia

Expression for Atypical Chronic Myeloid Leukemia

Search GEO for disease gene expression data for Atypical Chronic Myeloid Leukemia.

Pathways for Atypical Chronic Myeloid Leukemia

GO Terms for Atypical Chronic Myeloid Leukemia

Biological processes related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

(show all 17)
# Name GO ID Score Top Affiliating Genes
1 phosphorylation GO:0016310 9.81 ABL1 FGFR1 JAK2 PDGFRA
2 protein phosphorylation GO:0006468 9.78 ABL1 FGFR1 JAK2 PDGFRA
3 MAPK cascade GO:0000165 9.71 FGFR1 JAK2 PDGFRA
4 regulation of cell proliferation GO:0042127 9.67 ABL1 FGFR1 JAK2
5 positive regulation of cytosolic calcium ion concentration GO:0007204 9.61 ABL1 JAK2 PDGFRA
6 peptidyl-tyrosine autophosphorylation GO:0038083 9.57 ABL1 JAK2
7 thymus development GO:0048538 9.56 ABL1 ASXL1
8 phosphatidylinositol-mediated signaling GO:0048015 9.55 FGFR1 PDGFRA
9 chondrocyte differentiation GO:0002062 9.52 FGFR1 RUNX1
10 regulation of actin cytoskeleton reorganization GO:2000249 9.46 ABL1 PDGFRA
11 protein autophosphorylation GO:0046777 9.46 ABL1 FGFR1 JAK2 PDGFRA
12 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.43 FGFR1 JAK2 PDGFRA
13 negative regulation of cell-cell adhesion GO:0022408 9.4 ABL1 JAK2
14 regulation of myeloid cell differentiation GO:0045637 9.37 CSF3R RUNX1
15 positive regulation of phospholipase C activity GO:0010863 9.32 FGFR1 PDGFRA
16 peptidyl-tyrosine phosphorylation GO:0018108 9.26 ABL1 FGFR1 JAK2 PDGFRA
17 platelet-derived growth factor receptor signaling pathway GO:0048008 8.8 ABL1 JAK2 PDGFRA

Molecular functions related to Atypical Chronic Myeloid Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 9.77 ABL1 FGFR1 JAK2 PDGFRA RUNX1
2 kinase activity GO:0016301 9.62 ABL1 FGFR1 JAK2 PDGFRA
3 protein kinase activity GO:0004672 9.46 ABL1 FGFR1 JAK2 PDGFRA
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 FGFR1 PDGFRA
5 non-membrane spanning protein tyrosine kinase activity GO:0004715 9.4 ABL1 JAK2
6 SH2 domain binding GO:0042169 9.26 ABL1 JAK2
7 Ras guanyl-nucleotide exchange factor activity GO:0005088 9.13 FGFR1 JAK2 PDGFRA
8 protein tyrosine kinase activity GO:0004713 8.92 ABL1 FGFR1 JAK2 PDGFRA

Sources for Atypical Chronic Myeloid Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
27 GO
28 GTR
29 HGMD
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 MedGen
41 MeSH
42 MESH via Orphanet
43 MGI
45 NCI
46 NCIt
47 NDF-RT
50 NINDS
51 Novoseek
53 OMIM
54 OMIM via Orphanet
58 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....